The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

Fierce Pharma -------- Biopharma's largest companies have faced a tumultuous year. Amid pricing pushback, payer maneuvering, biosim threats, manufacturing setbacks and other challenges, analysts with Mizuho calculated which drugmakers have managed to succeed on the stock markets this year—and which companies have struggled. Most big drugmakers Mizuho covers in the U.S. have posted share price increases in 2017, except for Bristol-Myers Squibb, which lost 4% of its value since the start of the year. On the upside, AbbVie and Eli Lilly led the group at 13% and 12% share price growth, respectively. Merck and Pfizer each posted single-digit price gains. The stock performance figures are as of Aug. 4. To learn more click on the picture below to read the article.